Ironwood Pharmaceuticals Inc. Class A (IRWD)
$3.95
$-0.02
(-0.50%)
As on 11-Sep-2026 10:37EDT
Market cap
$704 Mln
Revenue (TTM)
$389 Mln
P/E Ratio
5.4
P/B Ratio
2.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-5.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
4.2
-
Debt to Equity
-2.4
-
Book Value
$--
-
EPS
$0.8
-
Face value
--
-
Shares outstanding
165,239,947
10 Years Aggregate
CFO
$440.27 Mln
EBITDA
$505.10 Mln
Net Profit
$-1,021.16 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ironwood Pharmaceuticals Inc. Class A (IRWD)
| 17.2 | -2.5 | 17.9 | 243.5 | -21.8 | -20.2 | -10.0 |
|
BSE Sensex
| -11.7 | -4.8 | 1.1 | -8.2 | 3.9 | 5.1 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ironwood Pharmaceuticals Inc. Class A (IRWD)
| -23.9 | -61.0 | -7.7 | 6.3 | 2.4 | -14.4 | 53.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ironwood Pharmaceuticals Inc. Class A (IRWD)
|
4.0 | 703.9 | 389.3 | 129.9 | 40.9 | -- | 5.4 | 2.6 |
| 84.6 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 259.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 74.8 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 56.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 106.5 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 350.5 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 116.6 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 537.2 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 586.5 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Ironwood Pharmaceuticals Inc. Class A (IRWD)
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase... type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Read more
-
Executive Chairman of the Board
Ms. Julie H. McHugh
-
Executive Chairman of the Board
Ms. Julie H. McHugh
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Ironwood Pharmaceuticals Inc. Class A (IRWD)
What is the current share price of Ironwood Pharmaceuticals Inc Class A (IRWD) Today?
The share price of Ironwood Pharmaceuticals Inc Class A (IRWD) is $3.95 (NASDAQ) as of 11-Sep-2026 10:37 EDT. Ironwood Pharmaceuticals Inc Class A (IRWD) has given a return of -21.77% in the last 3 years.
What is the current PB & PE ratio of Ironwood Pharmaceuticals Inc Class A (IRWD)?
The P/E ratio of Ironwood Pharmaceuticals Inc Class A (IRWD) is 5.39 times as on 04-Sep-2026.
The P/B ratio of Ironwood Pharmaceuticals Inc Class A (IRWD) is 2.59 times as on 04-Sep-2026, a 51 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
24.94 |
-2.29 |
2024 |
807.56 |
-2.36 |
2023 |
-1.78 |
-5.15 |
2022 |
13.11 |
3.52 |
2021 |
3.65 |
3.19 |
What is the 52 Week High and Low of Ironwood Pharmaceuticals Inc Class A (IRWD)?
The 52-week high and low of Ironwood Pharmaceuticals Inc Class A (IRWD) are Rs 5.78 and Rs 1.23 as of 11-Sep-2026.
What is the market cap of Ironwood Pharmaceuticals Inc Class A (IRWD)?
Ironwood Pharmaceuticals Inc Class A (IRWD) has a market capitalisation of $ 704 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Ironwood Pharmaceuticals Inc Class A (IRWD)?
Before investing in Ironwood Pharmaceuticals Inc Class A (IRWD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.